These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37655058)

  • 1. Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing.
    Argüelles-Arias F; Valdés Delgado T; Maldonado Pérez B; González Antuña J; Castro Laria L
    Therap Adv Gastroenterol; 2023; 16():17562848231191670. PubMed ID: 37655058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing.
    Argüelles-Arias F; Rodriguez González FJ; González Antuña J; Castro Laria L; Gutiérrez Martinez F; Alcaín Martinez G; Maldonado Pérez B; Camargo Camero R; Martos Van Dussen JV; Fernández Castañer A; Valdés Delgado T
    Inflamm Bowel Dis; 2024 Jul; ():. PubMed ID: 39082955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn's Disease With a Loss of Response.
    Heron V; Li Fraine S; Panaccione N; Restellini S; Germain P; Candido K; Bernstein CN; Bessissow T; Bitton A; Chauhan UK; Lakatos PL; Marshall JK; Michetti P; Seow CH; Rosenfeld G; Panaccione R; Afif W
    J Can Assoc Gastroenterol; 2022 Oct; 5(5):208-213. PubMed ID: 36196277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.
    Dubinsky M; Ma C; Griffith J; Crowell M; Neimark E; Kligys K; O'Connell T
    Adv Ther; 2023 Sep; 40(9):3896-3911. PubMed ID: 37368103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn's Disease.
    Straatmijer T; Biemans VBC; Moes DJAR; Hoentjen F; Ter Heine R; Maljaars PWJ; Theeuwen R; Pierik M; Duijvestein M; van der Meulen-de Jong AE;
    Dig Dis Sci; 2023 Jun; 68(6):2647-2657. PubMed ID: 36920666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study.
    Yao JY; Zhang M; Wang W; Peng X; Zhao JZ; Liu T; Li ZW; Sun HT; Hu P; Zhi M
    BMC Gastroenterol; 2021 Oct; 21(1):380. PubMed ID: 34663208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of ustekinumab trough levels during induction and maintenance therapy with regard to disease activity status in difficult to treat Crohn disease patients.
    Mechie NC; Burmester M; Mavropoulou E; Pilavakis Y; Kunsch S; Ellenrieder V; Amanzada A
    Medicine (Baltimore); 2021 Mar; 100(11):e25111. PubMed ID: 33725990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.
    Bressler B; Jones J; In TSH; Lan T; Iconaru C; Marshall JK
    Adv Ther; 2023 Oct; 40(10):4421-4439. PubMed ID: 37507652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimodal dynamic ultrasound approach as predictor of response in patients with Crohn's disease treated with ustekinumab.
    Ainora ME; Liguori A; Mignini I; Cintoni M; Galasso L; Laterza L; Lopetuso LR; Garcovich M; Riccardi L; Gasbarrini A; Scaldaferri F; Zocco MA
    Therap Adv Gastroenterol; 2024; 17():17562848241259289. PubMed ID: 38912296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
    Smith PJ; Critchley L; Storey D; Gregg B; Stenson J; Kneebone A; Rimmer T; Burke S; Hussain S; Yi Teoh W; Vazeille S; Serna S; Steel A; Derbyshire E; Collins P; Dibb M; Flanagan P; Probert C; Verma AM; Subramanian S
    J Crohns Colitis; 2022 Sep; 16(9):1436-1446. PubMed ID: 35390141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short and Long-Term Effectiveness of Ustekinumab in Patients with Crohn's Disease: Real-World Data from a German IBD Cohort.
    Kubesch A; Rueter L; Farrag K; Krause T; Stienecker K; Hausmann J; Filmann N; Dignass A; Stein J; Blumenstein I
    J Clin Med; 2019 Dec; 8(12):. PubMed ID: 31817134
    [No Abstract]   [Full Text] [Related]  

  • 12. Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn's Disease.
    Bertin L; Barberio B; Gubbiotti A; Bertani L; Costa F; Ceccarelli L; Visaggi P; Bodini G; Pasta A; Sablich R; Urbano MT; Ferronato A; Buda A; De Bona M; Del Corso G; Massano A; Angriman I; Scarpa M; Zingone F; Savarino EV
    J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38541765
    [No Abstract]   [Full Text] [Related]  

  • 13. Ustekinumab Tissue and Serum Levels in Patients With Crohn's Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction.
    Proietti E; Pauwels RWM; van der Woude CJ; Doukas M; Oudijk L; Peppelenbosch MP; Grohmann U; Crombag MBS; de Vries AC; Fuhler GM
    Inflamm Bowel Dis; 2023 Jul; 29(7):1038-1046. PubMed ID: 35917118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis on the efficacy of dual vein induction therapy of Ustekinumab in complex perianal fistulizing Crohn's disease].
    Zhang DL; Shao XX; Hu DY; Lin DP; Wu H; Jiang Y
    Zhonghua Yi Xue Za Zhi; 2023 Nov; 103(41):3301-3306. PubMed ID: 37926575
    [No Abstract]   [Full Text] [Related]  

  • 15. The Long-Term Clinical Effectiveness of Ustekinumab in Antitumor Necrosis Factor-Experienced Crohn's Disease Patients.
    Altuwaijri M; Hakami L; Alharbi O; Almadi M; Alshankiti S; Aljebreen A; Azzam N
    Cureus; 2022 Aug; 14(8):e28536. PubMed ID: 36185868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and Safety of Ustekinumab for Ulcerative Colitis: A Brazilian Multicentric Observational Study.
    Parra RS; Chebli JMF; de Azevedo MFC; Chebli LA; Zabot GP; Cassol OS; de Sá Brito Fróes R; Santana GO; Lubini M; Magro DO; Imbrizi M; Moraes ACDS; Teixeira FV; Alves Junior AJT; Gasparetti Junior NLT; da Costa Ferreira S; Queiroz NSF; Kotze PG; Féres O
    Crohns Colitis 360; 2024 Apr; 6(2):otae023. PubMed ID: 38681979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effectiveness and persistence rate of ustekinumab dose intensification in a South East Asian inflammatory bowel disease center.
    Lim CT; Tay SW; Elangovan S; Ong WC; Lim GH; Salazar E; Chan WPW; Tan MTK
    J Gastroenterol Hepatol; 2024 Aug; 39(8):1544-1553. PubMed ID: 38680014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extra intravenous Ustekinumab reinduction is an effective optimization strategy for patients with refractory Crohn's disease.
    Yao J; Peng X; Zhong Y; Su T; Bihi A; Zhao J; Liu T; Wang W; Hu P; Zhang M; Zhi M
    Front Med (Lausanne); 2023; 10():1105981. PubMed ID: 37554510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
    Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effectiveness and safety of ustekinumab in youth with refractory inflammatory bowel disease: A retrospective cohort study.
    Alhadab A; Almarhoon A; AlAlwan A; Hammo A
    Saudi J Gastroenterol; 2024 Apr; ():. PubMed ID: 38597337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.